Connect with us

Psilocybin

Medspresso Joins the Speciality Coffee Association of South Africa

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / February 28, 2022 / WUHAN GENERAL GROUP, INC. (WUHN) (“WGG” or the “Company”), a bioceutical company focused…

Published

on

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / February 28, 2022 / WUHAN GENERAL GROUP, INC. (WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:

Medspresso is pleased to announce its membership in the Speciality Coffee Association of South Africa (SCASA).

SCASA is a non-profit organization that brings together coffee industry participants from various sectors in Southern Africa. Its objective is to promote the appreciation of high-quality coffees as well as the recognition of coffee industry workers in Southern Africa.

The organization’s goal is to grow the South African coffee market and support all stakeholders through its motto of a “United Passion for Coffee“, including the commitment to quality, the spirit of cooperation, sensitivity to the environment, and the consciousness of social issues.

SCASA is a representative for the World Coffee Events and the World Barista Competition and promotes contests associated with these organizations.

“Officially being a member of SCASA adds new depth to the brand. It’s absolutely amazing to be part of such a prestigious association that serves the coffee community through so many channels and initiatives. At Medspresso we focus on continually enhancing the quality of our products and the value proposition to our consumers, and our new membership with SCASA will allow us to do just that.” – says Michael Sachar, CEO of M2Bio Sciences Food and Beverage.

Medspresso continues to concentrate on producing coffee of exceptional quality through its principle of 3E’s: ExtraordinaryElegant, and Exquisite.

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx, Medspresso, and Liviana brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

Publicly traded company (OTC Pink: WUHN)
Website: www.m2bio.co
E-mail: info@m2bio.co
Follow us on Twitter: https://twitter.com/Medspresso
Follow us on Facebook: https://www.facebook.com/Medspresso
Follow us on YouTube: https://www.youtube.com/channel/Medspresso
Follow us on Instagram: https://www.instagram.com/medspresso.official

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc.

The post Medspresso Joins the Speciality Coffee Association of South Africa appeared first on CannabisFN.

Read More

Trending